Our proprietary technology is based on polymersomes which we call Artificial Cell Membranes (“ACMs”). These ACMs are nanoscale vesicles which are conceptually very similar to liposomes, except that they are made from di-block or tri-block copolymers instead of lipids. Over more than 15 years of intensive R&D we have perfected, and patented, techniques of making these ACMs and incorporating membrane proteins into their walls such that these proteins are stable and correctly presented and elicit strong immune responses. We have shown these ACMs to have numerous advantages for both veterinary and human vaccines including viral, bacterial, and oncological diseases.


We are developing vaccines against a few selected targets. These targets are within the areas of infectious disease and oncology. Our targets are currently confidential, however, we intend to make them public as soon as practical, and so we encourage you to contact us or revisit out site to see what these are.